EWNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Edwards Lifesciences Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$87.22+0.62 (+0.72%)
Close on Oct 19, 2026
- Market cap
- $50.38B
- P/E (TTM)
- 50.1
- Dividend yield
- –
Edwards Lifesciences Corp revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $3.76B | $3.64B | $3.54B | $3.45B | $3.35B | $3.26B | $3.21B | $3.14B | $3.07B | $3.02B | $2.95B | $2.64B | 57.7% | +12.2% |
| Europe | $1.68B | $1.62B | $1.52B | $1.45B | $1.38B | $1.34B | $1.32B | $1.28B | $1.24B | $1.21B | $1.18B | $1.06B | 25.8% | +21.4% |
| Rest of World | $712.40M | $679.90M | $652.30M | $630.10M | $611.10M | $586.40M | $572.00M | $560.80M | $548.30M | $543.20M | $531.10M | $602.50M | 10.9% | +16.6% |
| Japan | $364.60M | $363.50M | $354.70M | $353.10M | $344.40M | $335.60M | $339.80M | $353.20M | $356.70M | $357.70M | $350.80M | $419.10M | 5.6% | +5.9% |
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Transcatheter Aortic Valve Replacement | $4.77B | $4.64B | $4.49B | $4.36B | $4.24B | $4.14B | $4.11B | $4.05B | $3.99B | $3.94B | $3.88B | $3.77B | 73.2% | +12.5% |
| Transcatheter Mitral and Tricuspid Therapies | $674.60M | $610.50M | $550.60M | $500.00M | $445.90M | $394.40M | $352.10M | $303.00M | $264.30M | $228.90M | $197.60M | $173.10M | 10.4% | +51.3% |
| Critical Care | – | – | – | – | – | – | – | – | – | $957.50M | $928.10M | $902.60M | – | – |
| Surgical Structural Heart | – | – | $1.03B | $1.02B | $1.00B | $983.10M | $981.30M | $967.90M | $958.00M | $966.50M | $932.60M | $895.30M | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | – | – | – | – | – | – | – | $3.87B | $3.80B | $3.74B | $3.51B | $3.14B | – | – |
| Europe | – | – | – | – | – | – | – | $1.48B | $1.45B | $1.41B | $1.33B | $1.21B | – | – |
| Japan | – | – | – | – | – | – | – | $465.60M | $470.00M | $476.70M | $452.40M | $405.10M | – | – |
| Rest of World | – | – | – | – | – | – | – | $786.90M | $773.50M | $765.00M | $709.20M | $589.00M | – | – |
From the segment and revenue-disaggregation notes of Edwards Lifesciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.